

HEMATOLOGY DISEASE SITE COMMITTEE

DATE -- FRIDAY APRIL 29, 2022, 11:00 AM – 1:00 PM EASTERN TIME

CO-CHAIRS : ANTHONY REIMAN, SARIT ASSOULINE
SENIOR INVESTIGATORS: LOIS SHEPHERD, ANNETTE HAY

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To identify and address, through clinical trial and translational research, the disease burden associated with hematologic malignancies in Canada
- To identify clinical trial research opportunities in hematologic malignancies within the Canadian Cancer Trials Group
- To integrate current knowledge regarding therapeutics and tumour biology in hematologic malignancies in trial concept development and conduct
- To integrate and apply new clinical trial methodologies in hematologic malignancies in the Canadian Cancer Trials Group research agenda
- To provide a learning and mentoring environment supportive to new investigators

11:00 am Introduction and Welcome

11:05 am Overview of Current and Planned Trials Portfolio

S. Assouline

11:15 am Accomplishments in the past year

T. Reiman

11:25 am Highlighting Ongoing/Soon to Open Studies

**CLC3
MYC2
HD11
HDC1
LY17/LY18
myeloMATCH suite**

**V. Banerji
C. Venner
K. Savage/A. Prica
K. Davison
J. Kuruvilla
L. Savoie/S. Assouline**

12:20 pm Guest Speaker - Myeloma

Dr. Noopur Raje

12:50pm Closing Remarks

T. Reiman/S. Assouline

1:00 pm Meeting Adjourned